The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net revenues from external customers | 344,229 |
| Personnel costs | 209,816 |
| Organizational and marketing costs | 51,545 |
| Inventory usage | 21,821 |
| Clinical studies and publication costs | 8,777 |
| Professional services | 10,928 |
| Other segment items | 65,500 |
| Net (loss) income | -24,158 |
| Depreciation and amortization | 40,771 |
| Stock-based compensation expense | 45,893 |
| Net gains on equity securities | 1,466 |
| Deferred income taxes | -6,228 |
| Accretion of discounts on marketable investment securities | 4,219 |
| Other | -153 |
| Accounts receivable | -6,876 |
| Prepaid expenses and other current assets | 544 |
| Inventory | 2,142 |
| Operating lease assets | -1,372 |
| Other assets | 366 |
| Accounts payable | 3,078 |
| Operating lease liabilities | -1,275 |
| Accrued compensation | 5,732 |
| Other accrued and current liabilities | 870 |
| Net cash provided by (used in) operating activities | 64,347 |
| Purchases of marketable investment securities | 188,714 |
| Proceeds from maturities of marketable investment securities | 189,200 |
| Proceeds from sale of equity securities | 1,533 |
| Purchases of debt securities classified as held-to-maturity | 5,569 |
| Asset acquisition, net of cash and cash equivalents acquired | 18,727 |
| Issuance of loan receivable | 2,114 |
| Purchases of property and equipment | 36,021 |
| Proceeds from sale of property and equipment | 45 |
| Net cash used in investing activities | -60,367 |
| Proceeds from exercise of common stock options | 2,206 |
| Payment of employees taxes on vested restricted stock units | 11,657 |
| Proceeds from contributions to the employee stock purchase plan | 2,416 |
| Repayment of principal portion of finance lease liabilities | 115 |
| Proceeds from lease incentives received | 190 |
| Proceeds from issuance of term debt | 0 |
| Net cash (used in) provided by financing activities | -6,960 |
| Net change in cash and cash equivalents | -2,980 |
| Beginning of year | 119,709 |
| End of year | 116,729 |
CASTLE BIOSCIENCES INC (CSTL)
CASTLE BIOSCIENCES INC (CSTL)